ReviewBritish journal of clinical pharmacology2006
Drug development in oncology: classical cytotoxics and molecularly targeted agents.
Review in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Pooled it
- BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug Responses.Cancer research · 2026Article
- National Cancer Institute Cancer Treatment Tolerability Consortium: Current status and future directions.Cancer · 2025Article
- Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.Clinical and translational science · 2025Article
- Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules.Cancer chemotherapy and pharmacology · 2025Article
- Combination of vascular surgery with novel vascular targeting agents as cancer therapeutics.Frontiers in oncology · 2025Review
- Development of caspase-3-selective activity-based probes for PET imaging of apoptosis.EJNMMI radiopharmacy and chemistry · 2024Article
- An insight into the anticancer potentials of lignan arctiin: A comprehensive review of molecular mechanisms.Heliyon · 2024Review
- Optimized Synthesis of Poly(Lactic Acid) Nanoparticles for the Encapsulation of Flutamide.Gels (Basel, Switzerland) · 2024Article
- PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.CPT: pharmacometrics & systems pharmacology · 2023Article
- Enriching single-arm clinical trials with external controls: possibilities and pitfalls.Blood advances · 2023Article
- Article
- The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives.Gynecologic oncology reports · 2022Article
- Article
- Revisiting the Resazurin-Based Sensing of Cellular Viability: Widening the Application Horizon.Biosensors · 2022Article
- Bioymifi, a novel mimetic of TNF-related apoptosis-induced ligand (TRAIL), stimulates eryptosis.Medical oncology (Northwood, London, England) · 2021Article
- [European journal of nuclear medicine and molecular imaging · 2021Article
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.Cancer chemotherapy and pharmacology · 2021Review
- A recent development of new therapeutic agents and novel drug targets for cancer treatment.SAGE open medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is an apparent need to improve the speed and efficiency of oncological drug development. Furthermore, strategies traditionally applied to the development of standard cytotoxic chemotherapy may not be appropriate for molecularly targeted agents. This is particularly the case for exploratory Phase 1 and 2 trials. Conventional approaches to determine dose based on maximum tolerability and efficacy based on objective tumour response may not be suitable for targeted agents, since many of them have a wide therapeutic index and inhibit tumour growth without demonstrable cytotoxicity. Instead, exploratory trials of targeted agents may have to focus on other end-points such as pharmacological effects and disease stabilization. Thus, there is an increasing interest in making the best possible use of biomarkers and pharmacogenomics in early phases of drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.